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Background: There is currently insufficient data describing how new medications are provided to older adult ambula-
tory patients with dementia in the United States (US).
Objectives: To describe characteristics of ambulatory care visits for adults≥65 years old and investigate differences in
prescribing of new medications between patients with and without dementia.
Methods: We conducted a population-based cross-sectional study using the 2016 National Ambulatory Medical Care
Survey (NAMCS) in the US. Non-perioperative ambulatory care visits of patients≥65 years old with samplingweights
were used to provide national estimates of visits. Baseline characteristics were compared between visits for patients
with and without dementia using Pearson's chi square or Student's t-tests. We used multivariable logistic regression
to estimate the odds of receiving a new medication.
Results: 218,182,131 non-perioperative ambulatory care visits of patients≥65 years oldwere included, 2.1% ofwhich
were for patients with dementia; these patients were older on average and had more comorbidities and higher ambu-
latory care utilization than those without dementia. New medications were provided at 26.3% of visits for patients
with dementia. After adjusting for confounders, there was no statistically significant difference in odds of a new med-
ication being provided between visits for patients with andwithout dementia (odds ratio [OR], 0.555; 95% confidence
interval [CI], 0.183–1.678). Differences were seen in the provision of cholinesterase inhibitors, antipsychotics, and
central nervous system agents at visits for patients with dementia (p = 0.0011, <0.0001, and 0.0011 respectively).
Conclusion:While fewer visits for patients with dementia provided newmedications compared to patients without de-
mentia, after adjusting for confounders no significant difference were identified. Significant differences were seen in
the classes of new medications provided. Further investigation is needed to evaluate new medication usage and the







Dementia, a condition that results in memory or cognitive decline lead-
ing to functional loss, is a serious concern for individuals 65 years and
older, with an estimated global prevalence of 50 million, and more than
fivemillion older Americans reported to have dementia in 2020.1–3 In addi-
tion to the high burden of dementia among older adults (~10% of people
65 years and older are afflicted),4 dementia impacts women and racial
and ethnic minorities disproportionately. This is evidenced by the fact
that almost two thirds of older Americans with dementia are women,5
and despite the majority of Americans identifying as non-Hispanic ethnic-
ity, older African Americans and Hispanics are up to twice as likely to
have dementia, and aremore likely to have a missed dementia diagnosis.5,6
As the number of older Americans rapidly grows, the population with de-
mentia is expected to rise almost three fold by 2050,5,7,8 thus further in-
creasing the social and economic burden of this disease state.9
A disease of aging, dementia often impacts patients with numerous co-
morbid conditions. This multimorbidity among patients with dementia has
many effects, including increased healthcare utilization before and after
diagnosis10–12 and use of many medications. Total healthcare payments in
2020 for people with dementia ages 65 years and older were estimated to
be $305 billion,2 significantly higher than costs for older adults without de-
mentia. Existing evidence suggests that patients with dementia had signifi-
cantly higher annual Medicare and Medicaid expenditures at $10,814 and
$6234 comparedwith thosewithout dementia at $5953 and $1962, respec-
tively, using cohort-based simulation models from diagnosis until
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death.13,14 The complexmedication regimens to treat patients with demen-
tia and their associated comorbidities,13,14 may result in the need for longer
ambulatory care visits and the expertise of multiple providers.11–15 While
specialist care is important in managing the complex medical care of
older adults with dementia, it can also lead to the receipt of more
medications.15 Use of five or more medications concurrently is known as
polypharmacy, and older adults more commonly report polypharmacy
than their younger counterparts (ranging from about 20–80%9,23,25).
Even though use of multiple medications may be appropriate to treat mul-
tiple conditions, polypharmacy has been associated with increased odds of
potentially inappropriate prescribing in patients with dementia.16–18
Thus, without adequate healthcare coordination, patients with demen-
tia are at a heightened risk for preventable medical errors.19–21 Utilizing
the full spectrum of available healthcare providers can alleviate physician
burden,22 and given that medication management is a significant compo-
nent to improving care in this population, pharmacists are well-suited to
augment the healthcare team for patients with dementia. For chronic dis-
ease such as diabetes and hypertension, pharmacists already provide ser-
vices including improving medication adherence, providing patient
education, monitoring laboratory values or adverse effects of medications
to ensure safety and effectiveness, and conducting prior authorizations in
hospital, ambulatory, and community settings.23 Additionally, recent stud-
ies have demonstrated pharmacists' positive impact on other chronic dis-
ease state management in the ambulatory care setting.24,25 Outside of the
U.S, research has recognized the potential benefits of pharmacists in de-
mentia care in both hospital and community settings.26,27 While the role
of pharmacists in dementia care may already be defined in other countries
and for other chronic conditions, the active pharmacist involvement in de-
mentia care in the U.S. is not well established, especially in the outpatient
setting. Unlike other chronic conditions, dementia is unique in the fact
that treatment often requires caretaker assistance. Thus, pharmacists
could be a critical and underutilized resource to add to the ambulatory
healthcare team for patients with dementia.
Understanding the detailed characteristics of ambulatory healthcare
utilization such as frequency, length of visit, and types of medications pre-
scribed among patients with dementia is thus the first step in designing
targeted interventions to reduce inappropriate medication use among
older patients with dementia. Pharmacists specifically can improve care
by shortening lengthy visits, managing and reconciling high risk medica-
tions, ordering medication-related laboratory values, and executing follow
up visits relating solely to medication education and adjustment.
To date, there is a lack of information about newmedications provided
to older adults with dementia at ambulatory care visits in the U.S. As a re-
sult, it is unknown what types of medication related services pharmacists
could be most efficient in providing in ambulatory care settings for patients
with dementia to improve the current standard of care. The objectives of
this study were to 1) determine whether differences exist in the ordering
and providing of new medications at ambulatory care visits for older pa-
tients with dementia compared to visits for those without dementia after
controlling for known confounders, 2) evaluate whether specific therapeu-
tic classes of medications are differentially ordered or provided to patients
with and without dementia, and 3) describe characteristics of these visits
for older patients with and without dementia to provide information on
how these patients might differentially use ambulatory care services.
2. Methods
2.1. Patient population
In this study, we used the 2016 National Ambulatory Medical Care Sur-
vey (NAMCS) for data on new prescription and non-prescription medica-
tions that were ordered and/or provided at ambulatory care visits for
older adults with and without dementia. At the time this study was con-
ducted, 2016 was the most recent dataset provided by NAMCS. Data in-
cluded in NAMCS are collected by the National Center for Health
Statistics as a nationally representative electronic survey completed
annually by non-federally employed office-based physicians in a variety
of specialties.28 To ensure high specificity,29 the NAMCS uses a stratified
two stage sample design, selecting physicians, and then patient visits as
the unit of analysis. Each selected physician is randomly assigned a one-
week reporting period, during which a random sample of visits are entered
into a computerized form.28 Because NAMCS is deidentified and publicly
available, the study was exempted from institutional review board review
at the University of [removed for blinding purposes].
We included visits for patients ≥65 years of age. Visits were also ex-
cluded if the major reason for the visit was peri-surgical, due to situational
medication use that could confound national estimates for regular medica-
tion use.30
2.2. Identification of patients with dementia
In this cross-sectional study, visits for patients with dementia were com-
pared to visits for patients without dementia. Visits for patients with
Alzheimer's Disease and additional related dementias were identified
from the data collection form using the free-text diagnosis fields provided
by physicians, the binary indicator for Alzheimer's Disease/dementia, as
well as the presence of an ICD-10 code indicating dementia (G30.0,
G30.1, G30.8, G309. F01.50, F01.51, F02.80, F02.81, F03.90, F03.91,
F10.27, F10.97, F13.27, F13.97, F18.27, F18.97, F19.27, and F19.97). Be-
cause the survey is deidentified, it is technically possible the same patient
had multiple visits included in the 2016 NAMCS. However, this situation
is unlikely because the survey requires that the same patient would have
had to be randomly selected and seen twice during the one-week period
of physician report.
2.3. Medication information
As part of the NAMCS standard form, physicians record up to 30 medi-
cations from the patient's ElectronicHealth Record. TheNAMCSDrug Data-
base Coordinator then codes all medication items using Lexicon Plus®, a
proprietary database of Cerner Multum, Inc.31 In addition to medication
names, NAMCS collects information on whether the reported medication
is a new medication or has been continued from a previous visit.
The primary outcome of interest in this studywas the presence of one or
more new medications at the ambulatory care visit. A visit was considered
to lack newmedication(s) if: 1) no medications were listed for a visit, 2) all
medications listed were continued from previous visits, or 3) medication
new/continued status was unknown.
We also describe the therapeutic class of newmedications using the Lex-
icon Plus® nomenclature. Multum categorizes medications into a three-
level nested system, where level 1 is the broadest therapeutic classification
and level 3 is the most detailed classification. In this study, most medica-
tions are described using level 1 therapeutic classes, except central nervous
system (CNS) agents (Level 1=057), psychotherapeutic agents (Level 1=
242), and metabolic agents (Level 1 = 358), which were described using
the more detailed level 2 categories because these medications are espe-
cially relevant to the population of interest. While the grouping of medica-
tions into Multum therapeutic classifications is proprietary, more
information including all level 1, 2, and 3 classifications can be found in
the NAMCS documentation.31
2.4. Statistical analysis
To investigate whether newmedications were differentially provided at
outpatient visits for patients with dementia compared to visits for patients
without dementia, multivariable logistic regression was used to estimate
the adjusted odds ratio (aOR) and 95% confidence interval (CI), with p <
0.05 considered statistically significant. Due to the epidemiologic frame-
work, covariates included in the regression were not evaluated for their ef-
fect on new medication provision but rather as a control for confounding
and to describe baseline differences in visit and patient characteristics. De-
mographic characteristics included age, sex, ethnicity, race, region, tobacco
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use, source of payment, andwhether the patient had been seen before at the
practice. Visit characteristics included length of visit, multiple providers
seen, whether the physician was a primary care provider, and whether
the major reason for visit was related to a new problem or infection (see
Supplementary Table S1). Patient characteristics included the number of
chronic conditions, presence of ≥5 continued medications
(polypharmacy), and comorbidities (cancer, cerebral vascular disease, cor-
onary artery disease, depression, diabetes, chronic obstructive pulmonary
disease, sleep apnea, and asthma) (see Supplementary Table S2 for defini-
tions). In order to adjust for bias, covariates included in the model were se-
lected based on the existing literature and using directed acyclic graphs.
Additionally, we investigated whether the therapeutic classes of new med-
ications ordered or provided at visits differed for patients with and without
dementia utilizing Chi-squared or Student's t-tests.
We described ambulatory care visit and patient characteristics for adults
65 years and older using the sampling weights provided by NAMCS to pro-
vide national estimates. The CDC's National Center for Health Statistics cre-
ation of sampling weights is composed of four parts including 1) inflation
by reciprocals of the probabilities of selection, 2) adjustment for nonre-
sponse, 3) a ratio adjustment to fixed totals, and 4) weight smoothing.29,32
Normality for covariates of interest was assessed visually with Q-Q plots,
and normally distributed continuous variables were described using the
mean and standard deviation (SD), while the median and interquartile
range (IQR) were used to describe non-normally distributed variables.
Chi-squared or Student's t-tests were used to compare characteristics be-
tween groups as appropriate.
All statistical analyses were performed in SAS version 9.4 and reviewed
by three separate researchers.
3. Results
3.1. Visit and patient characteristics
In total, we included 13,165 of the recorded visits, amounting to a na-
tionally weighted 218,182,131 ambulatory care visits (see Fig. 1; all future
references are to weighted estimates). The majority of total ambulatory
care visits were in metropolitan areas for white, female patients between
65 and 74 years old whose primary insurance was Medicare (see Table 1).
Similarities between outpatient visits of patients with and without de-
mentia included white race, Medicaid and private payer status, location
in a metropolitan area, never utilizing tobacco, time with the physician,
and whether the visit was for a new patient or with multiple providers.
2.1% of the visitswere for patientswith dementia, whowere on average
older (p=0.0002), more underweight (p=0.02), hadmore comorbidities
(p = 0.01) such as depression (p = 0.0004), and higher ambulatory care
utilization than those without dementia (p = 0.002). Specifically, over
half of the visits for patients with dementia recorded that the patient had
five or more ambulatory care visits in the last 12 months. Additionally, sig-
nificantly more visits for patients with dementia were with a primary care
physician (p= 0.001) and located in the southern region (p = 0.01) com-
pared to visits for patients without dementia. The majority of these visits
were for a chronic, routine reasons (49.3%), while only 15.0% were
for a new problem. More visits for patients with dementia reported
polypharmacy (58.1 vs 44.0%), but this was not statistically significant
(p = 0.0944). Finally, visits for patients with dementia more commonly
recommended an “unspecified” follow up time (p = 0.01).
In contrast, the majority of visits of patients without dementia had a
greater focus on preventative care (15.9% vs. 13.7%), and a quarter of
these visits were related to a new problem. The average number of chronic
conditions and total medications reported at visits of patients without de-
mentia were 1.7 (p = 0.01) and 2.8 (p = 0.12), respectively. Although
the number of total medications was not statistically significant, both esti-
mates were lower in comparison to visits of patients with dementia. Addi-
tional details about the visits of patients with and without dementia can
be found in Table 1.
3.2. New medication(s)
In 2016, new medications were ordered or provided at 26.3% of visits
for older patients with dementia, compared to 35.1% of visits for older pa-
tients without dementia. After adjusting for known confounders (as noted
above), there was no difference in the odds of a new medication being or-
dered or provided between visits for patients with dementia and visits for
patients without dementia (aOR [95% CI] 0.555 [0.183–1.678]).
3.3. Most common new medication categories
The most common new medications ordered or provided to patients with
dementia were immunostimulants (vaccines), cardiovascular agents, cholines-
terase inhibitors, and coagulation modifiers (27.4, 17.2, 14.5, 8.3% respec-
tively; see Fig. 2). In contrast, the four most common classes of new
medications for patients without dementiawere topical agents, cardiovascular
agents, anti-infectives, and respiratory agents (17.7, 14.1,10.9, and 7.2% re-
spectively; see Fig. 2). More visits for patients with dementia recorded order-
ing or providing antipsychotics, cholinesterase inhibitors, and miscellaneous
central nervous system agents compared to visits for patients without demen-
tia (p=0.0011,<0.001, and 0.0011 respectively). Topical agents weremore
often provided at visits for patients without dementia (p=0.0084).
4. Discussion
Current literature investigating the dementia population focuses on
potentially inappropriate medications (PIMs), prescribing errors, and med-
ication adherence in multiple settings, such as nursing homes and the
No Demena visitsDemena visits
Inial 2016 NAMCS database visits
883,725,126
4,651,563 213,530,568 





Fig. 1. 2016 NAMCS investigated cohort (weighted).




Characteristics Total N (%) Dementia N (%) No Dementia N (%) P-value
Sample size, n
Weighted visits 218,182,131 4,651,563 213,530,568
Unweighted visits 13,165 73 13,092
Demographics
Age 0.0002
65–74 years old 119,691,873(54.85) 1,121,032(24.10) 118,570,842(55.53)
75–84 years old 71,964,003(32.98) 2,184,451(46.96) 69,779,552(32.68)
85+ years old 26,526,254(12.16) 1,346,080(28.94) 25,180,174(11.79)
Female Sex 123,362,558(56.54) 2,793,992(60.07) 120,568,566(56.46) 0.6455
Race/Ethnicity 0.8871
Not Hispanic/ Latino White 170,625,834(78.20) 3,753,919(80.70) 166,871,915(78.15)
Not Hispanic/ Latino Black 15,134,379(6.94) 374,512(8.05) 14,759,867(6.91)
Hispanic/Latino 23,084,695(10.58) 396,851(8.53) 22,687,844(10.63)
Not Hispanic/ Latino Other 9,337,223(4.28) 126,281(2.71) 9,210,942(4.31)
Region 0.0122
Northeast 41,053,103(18.82) 262,535(5.64) 40,790,568(19.10)
Midwest 52,272,814(23.96) 1,106,409(23.79) 51,166,405(23.96)
South 76,391,877(35.01) 2,534,743(54.49) 73,857,134(34.59)
West 48,464,336(22.21) 747,876(16.08) 47,716,461(22.35)
Metropolitan Area 196,392,814(90.01) 4,042,907(86.92) 192,349,907(90.08) 0.6126
Tobacco Use 0.1812
Never Smoker 87,623,630(40.16) 1,613,468 (34.69) 86,010,162 (40.28)
Former Smoker 60,274,320(27.63) 959,072(20.62) 59,315,248 (27.78)
Current Smoker 15,692,996(7.19) 214,861(4.62) 15,478,135 (7.25)
Missing 54,591,184(25.02) 1,864,161(40.08) 52,727,022(24.69)
Body Mass Index (BMI) 0.0214
Underweight (less than 18.5) 2,106,812(0.97) 158,568(3.41) 1,948,244(0.91)
Normal (18.5–24.99) 38,362,724(17.58) 1,544,997(33.21) 36,817,728(17.24)
Overweight (25–29.99) 48,816,527(22.37) 662,226(14.24) 48,154,301(22.55)
Obese (30 or greater) 50,239,274(23.03) 529,860(11.39) 49,709,413(23.28)
Missing 78,656,793(36.05) 1,755,911(37.75) 76,900,881(36.01)
Payment Type
Private Payer 89,587,855(41.06) 2,286,259(49.15) 87,301,595(40.88) 0.3100
Medicare 171,608,550(78.65) 4,115,495(88.48) 167,493,054(78.44) 0.0337
Medicaid 11,287,487(5.17) 405,128(8.71) 10,882,359(5.10) 0.3489
Self Pay 1,785,307(0.82) 30,063(0.65) 1,755,243(0.82) 0.8144
Other Payer 4,740,893(2.17) 4,671,292(2.19) 69,601(1.50) 0.5873
Visit Description
New patient 26,426,307(12.11) 424,702(9.13) 26,001,605(12.18) 0.4083
Number of Past Visits in Last 12 months 0.0002
0 visits 15,088,737(6.92) 75,390 (1.62) 15,013,347(7.03)
1 visit 33,711,220(15.45) 302,081(6.49) 33,409,139(15.65)
2–4 visits 75,304,145(34.51) 1,177,015(25.30) 74,127,131(34.71)
5+ visits 67,651,721(31.01) 2,672,375(57.45) 64,979,346(30.43)
Missing 26,426,307(12.11) 424,702(9.13) 26,001,605(12.18)
Major Reason For Visits n/a
New problem 54,493,619(24.98) 697,051(14.99) 53,796,568 (25.19)
Chronic, routine 99,203,843(45.47) 2,294,218(49.32) 96,909,625(45.38)
Chronic, flare up 22,536,123(10.33) 861,131(18.51) 21,674,992(10.15)
Preventative Care 34,672,953(15.89) 637,975(13.72) 34,034,977 (15.94)
Unknown 7,275,593(3.33) 161,187(3.47) 7,114,405(3.33)
Visit Related to a New Problem 0.1785
No 156,412,919(71.69) 3,793,324(81.55) 152,619,595(71.47)
Yes 54,493,619(24.98) 697,051(14.99) 53,796,568(25.19)
Missing 7,275,593(3.33) 161,187(3.47) 7,114,405(3.33)
Other Provider 67,142,842 (30.77) 1,437,468 (30.90) 65,705,374 (30.77) 0.9866
Multiple Providers Seen at Visit 110,084,453(50.46) 2,565,047(55.14) 107,519,406(50.35) 0.5994
Was the Physician the PCP 0.0001
No 133,663,742(61.26) 1,719,696(36.97) 131,944,046(61.79)
Yes 79,444,291(36.41) 2,909,986(62.56) 76,534,305(35.84)
Missing 5,074,097(2.33) 21,880(0.47) 5,052,217(2.37)
Time with Physician 0.6422
0–14 min 32,556,749(14.92) 530,521(11.41) 32,026,229(15.00)
15–29 min 128,113,928(58.72) 2,856,899(61.42) 125,257,030(58.66)
30–59 min 52,812,851(24.21) 1,044,719(22.46) 51,768,132(24.24)
60+ minutes 4,698,602(2.15) 219,424(4.72) 4,479,178(2.10)
Chronic Conditions
Pulmonary Disease 36,063,402(16.53) 48,995(1.05) 36,014,406(16.87) <0.0001
Diabetes 50,882,684(23.32) 764,639(16.44) 50,118,045(23.47) 0.2330
Depression 21,705,963(9.95) 1,175,478(25.27) 20,530,485(9.61) 0.0004
Cerebrovascular disease 10,675,765(4.89) 259,219(5.57) 10,416,546(4.88) 0.8100
Arthritis 48,876,054(22.40) 1,271,480(27.33) 47,604,573(22.29) 0.4900
Cancer 37,456,830(17.17) 612,672(13.17) 36,844,158(17.25) 0.5600
Coronary Artery Disease 33,514,131(15.36) 617,412(13.27) 32,896,719(15.41) 0.6900
Number of Chronic Conditions, Median (IQR) 1.70 (0.46–3.01) 2.40(1.20–3.60) 1.70(0.44–3.00) 0.0126
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Table 1 (continued)
Characteristics Total N (%) Dementia N (%) No Dementia N (%) P-value
*1.33% of this total variable is missing
Total Number of Medications, Median (IQR) 2.83 (0.13–7.80) 6.10(0.72–9.60) 2.80(0.11–7.70) 0.1238
*0 can represent no medications listed
Total Number of New Medications,
Median (IQR)
0.00 (0.00–0.46) 0.00(0.00–0.06) 0.00(0.00–0.47) 0.0109
*0 can represent no medications listed
Total Number of Continued Medications Median (IQR) 1.92 (0.00–7.22) 5.30(0.43–9.50) 1.90(0.00–7.10) 0.0566
*0 can represent no medications listed
Polypharmacy (5+ medications) 95,991,946 (44.00) 2,701,727 (58.08) 93,290,218 (43.67) 0.0944
Was a New Medication Provided 76,077,194(34.87) 1,224,355(26.32) 74,852,839(35.05) 0.2116
Was Any Medication Provided 167,610,449(76.82) 4,057,834(87.24) 163,552,615(76.59) 0.0974
Visit Follow Up
Return to referring physician/provider 6,711,143(3.08) 106,821(2.30) 6,604,322(3.09) 0.7000
Return to other physician/provider 16,944,412(7.77) 328,217(7.06) 16,616,195(7.78) 0.8500
Return in less than 1 week 6,541,087(3.00) 22,253(0.48) 6,518,835(3.05) 0.0400
Return in 1 week to less than 2 months 56,444,638(25.87) 1,907,217(41.00) 54,537,421(25.54) 0.0600
Return in 2 months or greater 93,176,292(42.71) 2,379,736(51.16) 90,796,556(42.52) 0.3400
Return at unspecified time 8,950,524(4.10) 36,268(77.97) 8,914,256(4.17) 0.0100
Return as needed 38,963,028(17.86) 230,459(4.95) 38,732,569(18.14) 0.0016
Combined unknown and blank variables as missing.
IQR = interquartile range.
Note: For NUMNEWandNUMCONT, the value ‘0’ can reflect the following situations: for NUMNEW, a) no drug listed; b) drug listed as continuedmedication only; or c) drug
listed but unknown whether new or continued; for NUMCONT, a) no drug listed; b) drug listed as new medication only, or c) drug listed but unknown whether new or
continued.
Fig. 2. Top 10 newmedication classes. Miscellaneous agents (Multum Lexicon categories 106–111, 114, 192, 270, 284, 320, 460, 491, and 497) include: antidotes, chelating
agents, cholinergic muscle stimulants, local injectable anesthetics, miscellaneous uncategorized agents, psoralens, illicit drugs, antirheumatics, antipsoriatics,
viscosupplementation agents, smoking cessation agents, phosphate binders, local injectable anesthetics with corticosteroids, and cation exchange resins. See NAMCS
documentation for more details on Multum Lexicon Therapeutic Classification Schema. Unknown (Multum Lexicon category 999): medications that could not be assigned
a Therapeutic Classification by the NAMCS Drug Database Coder. Other medications (Multum Lexicon Category): anorexiants (253), anticholinergic agents (312),
antiemetic/antivertigo agents (065), antineoplastics (020), biologicals (028), CNS stimulants (071), drugs used in alcohol dependence (378), general anesthetics (072),
genitourinary tract agents (113), immunological agents (254 except 437), muscle relaxants (073), nutritional products (115), radiologic agents (331), VMAT2 inhibitors
(496).
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community, rather the addition of new medications in an outpatient
setting.33–35 As seen in previous studies that used data from NAMCS, this
study has potentially important healthcare policy implications.29 Patients
with dementia had significantly more ambulatory care visits and contact
with general practitioners than patients without dementia.10,11 There was
a nearly 50% decrease in the odds of ordering or providing a new medica-
tion at ambulatory visits for patients with dementia in 2016. Although
there were no statistically significant differences in odds of new medica-
tions being provided between visits for patientswith andwithout dementia,
there were several statistically and clinically significant differences in the
therapeutic classes of medications that were ordered or provided to these
two patient groups(see Fig. 2).
At ambulatory visits for patients without dementia, topical agents, anti-
infectives, and respiratory agents were included in the most common med-
ication categories provided, but these agents were not provided as often to
patients with dementia (see Fig. 2). Of these medication categories, topical
agents were significantly different between visits of patients with and with-
out dementia. These medication differences, specifically with the respira-
tory agents, are likely driven by the fact that nearly 17% of visits for
patients without dementia reported a pulmonary disease comorbidity com-
pared to only 1% of visits for patients with dementia, a significant finding.
In addition, although statistically insignificant, approximately one fourth of
patients without dementia,10% greater than patients with dementia, were
being seen for a new problem. Authors hypothesize this may be an influen-
tial factor increasing anti-infective and topical therapies in patients without
dementia due to provider fears of undertreatment and symptom ambiguity
between bacterial and viral new, acute infections.36
Vaccines, cardiovascular agents, cholinesterase inhibitors, and coagu-
lant modifiers were the most common new medications prescribed to pa-
tients with dementia at outpatient visits, many of which, except
cardiovascular agents, were prescribedmuch less often in visits for patients
without dementia. Unsurprisingly, cholinesterase inhibitors, indicated for
treatment of dementia-related symptoms,37 were significantly different be-
tween visits of patients with and without dementia. Additionally, more
visits for patients with dementia provided antidepressants, antipsychotics,
and miscellaneous central nervous system agents compared to visits for pa-
tients without dementia. Many of these differences may be explained by a
difference in baseline risk for the comorbidities treated by these medica-
tions. For instance, agitation (commonly treated with antipsychotics) is
often comorbid with dementia,38 and depression has been reported in
nearly half of individuals with certain types of dementia.39
What is concerning, however, is the fact that many antipsychotics and
central nervous system agents are considered potentially inappropriate for
all older adults (see the Beers Criteria40), and the Food andDrug Administra-
tion specifically recommends against managing dementia-related psychosis
with antipsychotics.41 In addition to the finding that PIMs are being ordered
or provided at visits for patients with dementia more commonly than at
visits for patients without dementia, it is also important to highlight that
some of the more commonly provided newmedications at visits for patients
with dementia require close monitoring and dosage adjustments. Anticoag-
ulants, antipsychotics, and antidepressants can cause prolonged hospitaliza-
tions, life threatening conditions, and disability due to medication
errors.42–44 The role of a pharmacist in the outpatient setting to improve
the management of these potentially inappropriate or high-risk medications
may include patient education, adherence promotion, dosage adjustments,
adverse effect management, and laboratory and toxicity monitoring.45–49
Outside of the dementia population, existing evidence supports the
pharmacist's role in each of these therapeutic areas, discussed prior. For in-
stance, a review of pharmacist-managed outpatient anticoagulation ser-
vices demonstrated a reduction in healthcare utilization and major
thromboembolic events.50 A pharmacist-psychiatrist collaborative team re-
ported prescribing fewer antipsychotics and psychotropics, and an in-
creased number of nonpharmacologic interventions documented when
pharmacists were involved in patient care.45 Evenwhen PIMs are necessary
for patients with dementia in residential aged care facilities, pharmacists in
Australia have been shown to effectively reduce the dosages of PIMs.51
Though the role of pharmacists in the outpatient care of patients with de-
mentia in the U.S. has yet to be defined, there is evidence suggesting that
pharmacist-led medication therapy management (MTM) interventions in
the community setting can effectively reduce inappropriate medication use
for people with and without cognitive impairment.52,53 As the drug experts,
pharmacist could ensure appropriate medication therapy is chosen for indi-
vidualswith dementia alongwith providing alternative or augmentative solu-
tions, such as nonpharmacological options to combat psychosis.41Monitoring
drug appropriateness, adherence, interactions, toxicity, cost, safety, and effi-
cacy could assist combating the differences seen in visit utilization, comorbid-
ities, payment type, and unspecified follow up time. These findings coupled
with the observed differences in new medication classes prescribed to older
adults with dementia suggest that there is a need for pharmacist-led services
in the management of dementia at an ambulatory care setting.
To the authors' knowledge, this is the first study to evaluate the ordering
and provision of newmedications, regardless of appropriateness, in the outpa-
tient setting among older adults with dementia in the U.S. However, this study
is not without limitations. Although this study is purely descriptive and no
causal relationships can be concluded, exploratory research is an important as-
sessment tool because it reveals baseline associations that are required for fur-
ther investigation. For instance while the cross-sectional nature of this study
and the evaluation period of only one yearmay limit causal inference and gen-
eralizability, it provides convincing evidence that there is a significant need for
pharmacists to intervene and improve patient care in the U.S. Future studies
should evaluate trends over time, which could improve accuracy of these re-
sults (for instance, in 2016 only 73 unweighted visits for patients with demen-
tiawere recorded inNAMCS, explaining thewide confidence intervals seen for
the primary outcome in this study).
Our study has notable strengths. First, the NAMCS is a valuable source
to produce nationally weighted estimates of new medication orders and
provisions in the U.S. outpatient setting, and has been validated in prior
studies.29,32 Another strength of this studywas the careful adjustment of co-
variates, specifically for visits related to infection diagnosis or common
symptoms of infection. A prior study utilizing the NAMCS data found anti-
biotics were prescribed in 13.2% of ambulatory visits, and 18% of these an-
tibiotics were without a documented indication.54 In this study, anti-
infectives were reported as the third most common medication category
in older adult patients without dementia, while in patients with dementia
anti-infective therapy was not even within the top ten most common med-
ication categories. After adjustment for infection, it did not significantly im-
pact whether a new medication was provided to patients with or without
dementia. Because patients with dementia struggle with adherence tomed-
ications, infection's lack of influence on whether dementia patient's receive
a new medication at an ambulatory care visit serves as evidence that phar-
macists could also be helpful managing complex antibiotic regimens.55,56
5. Conclusion
Wewere not able to detect a difference in provision of newmedications
at ambulatory care visits for patients with and without dementia after ad-
justment for confounders. Nevertheless, there were significant differences
in the types of newmedications those with andwithout dementia were pro-
vided. Further investigation is needed to evaluate prescribing trends for
ambulatory patients with dementia, as well as the role of pharmacists in
the care of patients with dementia at an outpatient setting. Future opportu-
nities exist to evaluate the utilization and appropriateness of specific, new
medications in older adults with dementia over a period of time. Finally,
the benefits of pharmacist lead services on patients with dementia' medica-
tion efficacy, education, adherence, and safety in this setting have yet to be
explored.
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